Profile: NeurAxon discovers & develops next generation pain therapeutics that focus on the inhibition of neuronal nitric oxide synthase, an enzyme involved in modulating pain and central nervous system neuronal sensitization. Our NXN-188 is a dual-action small molecule incorporating both nNOS inhibition and 5-HT agonism for the treatment of acute migraine.